http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Bioimpedance vector analysis (BIVA) predicts morbidity following hepatic resection for cancer
Simone FAMULARO,Matteo DONADON,Linda ROCCAMATISI,Gabriele DI LUCCA,Edoardo BACCALINI,Marco ANGRISANI,Eloisa FRANCHI,Pio CORLEONE,Guido TORZILLI,Luca GIANOTTI 한국간담췌외과학회 2022 Annals of hepato-biliary-pancreatic surgery Vol.26 No.-
Transarterial Therapies for Hepatocellular Carcinoma
Lanza, Ezio,Donadon, Matteo,Poretti, Dario,Pedicini, Vittorio,Tramarin, Marco,Roncalli, Massimo,Rhee, Hyungjin,Park, Young Nyun,Torzilli, Guido S. Karger AG 2017 Liver cancer Vol.6 No.1
<P><B><I>Background:</I></B> The treatment of hepatocellular carcinoma (HCC) is still a major health issue because of its increasing incidence and because of the complexity of its management. Transarterial embolization (TAE) and transarterial chemoembolization (TACE) are two widely used locoregional therapies in the treatment of HCC, especially for unresectable intermediate and advanced HCCs. <B><I>Summary: </I></B>The modern use of TAE and TACE opens new scenarios for the treatment of unresectable HCC and has yielded interesting results. The present work describes the role of transarterial therapies for HCC and focuses on the different Western and Eastern approaches to the study of response predictors. <B><I>Key Messages: </I></B>Recent refinements in interventional radiology techniques and in HCC patient selection have facilitated better local control of the disease. The molecular profiling of HCC to predict the response to TACE and TAE will greatly help clinicians identify the optimum therapy.</P>
Di Tommaso, Luca,Franchi, Giada,Park, Young Nyun,Fiamengo, Barbara,Destro, Annarita,Morenghi, Emanuela,Montorsi, Marco,Torzilli, Guido,Tommasini, Maurizio,Terracciano, Luigi,Tornillo, Luigi,Vecchione, Wiley Subscription Services, Inc., A Wiley Company 2007 Hepatology Vol.45 No.3
<P>Hepatocellular nodules in cirrhosis include regenerative (large regenerative, LRN) and dysplastic (low and high grade, LGDN and HGDN) nodules, early and grade 1 HCC (eHCC-G1), and overt HCC. The differential diagnosis may be particularly difficult when lesions such as HGDN and eHCC-G1 are involved. We investigated the diagnostic yield of a panel of 3 putative markers of hepatocellular malignancy such as HSP70, glypican 3 (GPC3), and glutamine synthetase (GS). We selected 52 surgically removed nonmalignant nodules (15 LRNs, 15 LGDNs, 22 HGDNs) and 53 HCCs (10 early, 22 grade 1, and 21 grade 2-3) and immunostained them for HSP70, GPC3, and GS. The sensitivity and specificity of the individual markers for the detection of eHCC-G1 were 59% and 86% for GS, 69% and 91% for GPC3, and 78% and 95% for HSP70. We identified 2 main phenotypes: (1) all negative, seen in 100% LRN and LGDN, 73% HGDN and 3% eHCC-G1; (2) all positive, a feature detected in less than half the eHCC-G1. Using a 3-marker panel, when at least 2 of them, regardless which, were positive, the sensitivity and specificity for the detection of eHCC-G1 were respectively 72% and 100%; the most sensitive combination was HSP70+/GPC3+ (59%) when a 2-marker panel was used. Conclusion: The adopted panel of 3 markers is very helpful in distinguishing eHCC-G1 from dysplastic nodules arising in cirrhosis. (HEPATOLOGY 2007;45:725–734.)</P>
Filamin-A Expression Predicts Recurrence of Mass- Forming Cholangiocarcinoma after Hepatectomy
( Flavio Milana ),( Atteo Donadon ),( Artina Nebbia ),( Ristiana Soldani ),( Barbara Franceschini ),( Michela Anna Polidoro ),( Luca Di Tommaso ),( Ana Lleo De Nalda ),( Guido Torzilli ) 대한간학회 2020 춘·추계 학술대회 (KASL) Vol.2020 No.1
Aims: Recurrence of mass-forming cholangiocarcinoma (MFCCC) after hepatectomy is very high. A predictive marker of recurrence capable of personalizing follow-up and developing new targeted therapy would be beneficial. The overexpression of Filamin-A (FlnA), a cytoskeleton protein with scaffolding properties, has recently been associated with cell signalling, migration and adhesion in different tumors. The aim of this study was to test the expression of FlnA in a cohort of patients operated for MFCCC. Methods: A retrospective cohort of patients who underwent hepatic resection for MFCCC at Humanitas Clinical and Research Center between January 2004 and December 2018 was analyzed. FlnA expression was measured by calculating its intensity score at immunohistochemistry on paraffin-embedded tumor tissue sections for each patient. Such expression was then correlated with prognostic parameter of disease-free survival (DFS) by using survival analyses. Results: A total of 82 patients were considered. Median DFS in patients with low expression of FlnA was significantly increased in comparison with patients with high expression of FlnA (27 months vs. 10 months). Similarly, 5-year DFS was 30.8% vs. 10.9% (P=0.008). At the multivariate analysis number of tumor (HR=2.18; CI95% 1.98-3-21; P=0.004), tumor grade (HR=2.81; CI95% 1.77-5.12; P=0.001) and high expression of FlnA (HR=1.81; CI95% 0.98-2.31; P=.0.005) were found to be independently associated with worse DFS. Conclusions: FlnA expression is associated with higher risk of recurrence of MFCCC after hepatectomy. This finding provides important insights that would help physicians to personalize follow-up strategies and develop targeted therapy.